Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $117.3 million, representing a 15% year-over-year increase [10] - Achieved net income of $700,000, marking the first positive net income quarter in company history [10][11] - Adjusted EBITDA was $22 million, an increase of $16 million year-over-year, with an adjusted EBITDA margin of 19% [10] - Cash and cash equivalents at the end of the quarter were $98.3 million, up from $90.9 million in the prior quarter [11] - Operating cash flow was $14.8 million, up $3.8 million year-over-year, and free cash flow was $9.6 million, up $6 million year-over-year [11] Business Line Data and Key Metrics Changes - Average healthcare services clients increased to 4,467, up 298 from the prior year [10] - Total revenue per average healthcare services client was $26,249, up 7% year-over-year and flat quarter-over-quarter [10] Market Data and Key Metrics Changes - The acquisition of AccessOne is expected to expand the addressable market by approximately $6 billion, increasing the total addressable market to about $24 billion from approximately $10 billion [9][10] Company Strategy and Development Direction - The acquisition of AccessOne for $160 million is seen as a strategic move to enhance payment solutions and expand market reach [5][9] - The company aims to strengthen its financial profile and support clients with innovative payment solutions through this acquisition [9] - The introduction of new products like Voice AI is expected to drive engagement and revenue opportunities in the network solutions business [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the company, highlighting the importance of the AccessOne acquisition and the positive feedback on new products [5][21] - The company is maintaining its revenue outlook for fiscal year 2026 at a range of $472 million to $482 million and updating its adjusted EBITDA outlook to a range of $87 million to $92 million [12] Other Important Information - The company achieved positive operating cash flow and free cash flow for four consecutive quarters [11] - The AccessOne acquisition is expected to close in the third or early fourth quarter of fiscal 2026, subject to customary closing conditions and regulatory approvals [8] Q&A Session Summary Question: Development of AccessOne deal - Management has been monitoring AccessOne for years and believes it aligns well with their mission, making it a strategic acquisition [15] Question: Phreesia Voice AI product impact - The Voice AI product is expected to create more engagement opportunities and has received positive feedback from providers [20][21] Question: Revenue mix from AccessOne - The risk in the payment plans is shared between PNC Bank and the provider, with Phreesia not bearing the risk [35] Question: Growth rate of AccessOne - Management did not disclose historical growth rates but emphasized their intention to invest and grow AccessOne post-acquisition [53] Question: Customer overlap between Phreesia and AccessOne - There is some customer overlap, and more details will be shared post-acquisition [64] Question: AI product monetization - The company is currently monetizing AI products and sees significant market potential for these solutions [67]

Investor Presentation SECOND QUARTER | FISCAL YEAR 2026 2 OUR MISSION Making care easier every day Forward Looking Statements This presentation includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operational performance and may ...

This Health Startup Aims To Cut Down A Burdensome Chunk Of Doctors’ Paperwork https://t.co/TQOo80kJoN https://t.co/rJm1551qUy ...

Group 1 - The core announcement is about Diagnos Inc. conducting a non-brokered private placement of 10 units at a price of $10,000 per unit, aiming for gross proceeds of $100,000 [1][2] - Each unit consists of an unsecured convertible debenture with a 12-month term and an annual interest rate of 10%, which can be converted into common shares at a price of $0.28 per share [1][2] - Additionally, each warrant allows the holder to purchase one share at a price of $0.40 per share during the term [2] Group 2 - The proceeds from the private placement will primarily fund product development and commercialization of AI-based screening services, along with general and administrative expenses [2] - A director of the corporation has committed to subscribe for all units in the private placement [2] - All securities issued will be subject to a 4-month statutory hold period and require approval from the TSX Venture Exchange [3] Group 3 - Diagnos Inc. is focused on early detection of critical eye-related health issues using advanced AI technology to enhance diagnostic accuracy and improve patient outcomes globally [4]

Core Viewpoint - Clover Health positions itself as a leader in AI-enabled healthcare transformation, emphasizing the use of its proprietary AI platform, Clover Assistant, to enhance care delivery, particularly for seniors in underserved communities [1][2][6]. Group 1: AI and Healthcare Transformation - Clover Assistant is deployed across multiple states, serving thousands of healthcare providers and demonstrating measurable improvements in patient outcomes while reducing healthcare costs [2]. - The AI platform enables earlier disease detection, with data showing that diabetes can be diagnosed up to 3 years earlier and chronic kidney disease over 1.5 years earlier, leading to better health outcomes [7][22]. - AI is presented as a tool to enhance, not replace, the role of physicians, with the potential to improve care for all patients [4][14]. Group 2: Economic Impact and Cost Savings - AI-enabled care for congestive heart failure patients has resulted in 18% fewer hospitalizations and 25% fewer readmissions, while COPD patients experience 15% fewer hospitalizations and 18% lower 30-day readmissions [7][28]. - The Medical Cost Ratio for returning members whose doctors use Clover Assistant is over ten percent better than those who do not, allowing Clover to offer lower out-of-pocket costs for members [28]. Group 3: Empowering Providers - Clover Assistant acts as a central hub for a patient's care team, providing tailored views of patient data in specific clinical language, which helps combat physician burnout by automating tedious tasks [7][28]. - The platform is designed to integrate seamlessly into existing workflows, allowing practices to adopt it quickly with minimal training [13][19]. Group 4: Commitment to Responsible AI Use - The company advocates for the responsible use of AI, emphasizing that it should empower healthcare providers and improve patient care without denying or minimizing care [6][28]. - Clover Health calls for standardizing data interoperability to ensure AI can access comprehensive patient histories, which is essential for effective care delivery [29].

This Health Startup Aims To Cut Down A Burdensome Chunk Of Doctors’ Paperwork https://t.co/crV4bMkpko https://t.co/6EYxl68ums ...

Core Viewpoint - Aclarion, Inc. has appointed Greg Gould as the new Chief Financial Officer, bringing over 30 years of experience in public and private companies to drive growth and profitability [1][2][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][4] - The company's flagship product, Nociscan, is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [3][4] Leadership Transition - Greg Gould succeeds John Lorbiecki, who is retiring after establishing a strong financial foundation for Aclarion [1][2] - Gould has a proven track record, having raised over $450 million in public company debt and equity offerings and led multiple acquisitions [2][3] Market Opportunity - Chronic low back pain affects approximately 266 million people globally, presenting a significant market opportunity for Aclarion's innovative solutions [3] - Nociscan aims to improve surgical outcomes by objectively quantifying chemical biomarkers associated with disc pain [3][4] Technology and Innovation - Aclarion leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments [4][5] - The Nociscan platform integrates with MRI machines to provide critical insights into the location of low back pain, enhancing treatment strategies for physicians [5]

LEXINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the H.C.Wainwright 27th Annual Global Investment Conference in New York, NY. The Company is scheduled to present on Tuesday, September 9, 2025, at 11:00 a.m. ET. A l ...

Company Raises 2025 Revenue Outlook to $116 –$118 Million; Expects 2026 Revenue to be $128 –$130 Million SOMERSET, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (NASDAQ: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and AI-powered solutions for hospitals and medical practices nationwide, today announced updated financial guidance following the August 22, 2025 closing of its acquisition of the business assets of Medsphere Systems Corporation (“Medsphere”). For the ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Semler Scientific, Inc. ("Semler Scientific" or the "Company") (NASDAQ: SMLR) investors of a class action representing investors that bought securities between March 10, 2021 and April 15, 2025, inclusive (the "Class Period"). Semler Scientific investors have until October 28, 2025 to file a lead plaintiff motion. Investors are encouraged to co ...